Table 5.
The correlation between clinicopathological characteristics and EBV/HPV status (the HPV/EBV positive group was compared with other subgroups of breast cancer with various HPV/EBV status)
| Molecular Subtypes of Breast Cancer | |||
|---|---|---|---|
| Subtypes | HPV±/EBV± (%) | HPV+/EBV+ (%) | p-value |
| Luminal A | 19 (26.3) | 13 (18) | p = .02* |
| Luminal B | 10 (13.9) | 18 (0.3) | p = .08 |
| HER2-Positive | 2 (2.8) | 0 (0) | p = .06 |
| Triple Negative | 2 (2.8) | 8 (11.1) | p = .04* |
| Total | 33 (45.8) | 39 (54.2) | |
| Nottingham Histological Grade | |||
| Grade | |||
| I | 4 (5.5) | 10 (13.9) | p = .04* |
| II | 27 (37.5) | 13 (18.1) | |
| III | 10 (13.9) | 8 (11.1) | |
| Total | 41 (56.9) | 31 (43.1) | |
| Tumor Stage | |||
| Stages | |||
| Early Stage (I–II) | 20 (42.5) | 19 (40.4) | p = .04* |
| Advanced Stage (III–IV) | 1 (2.1) | 7 (14.9) | |
| Total | 21 (44.6) | 26 (55.3) | |
| Lymph Node Involvement | |||
| Status | |||
| Positive | 16 (23.9) | 14 (20.9) | p = .85 |
| Negative | 20 (29.8) | 17 (25.3) | |
| Total | 36 (53.7) | 31 (46.2) | |
| Tumor Type | |||
| IDC | 27 (37) | 32 (43.8) | p = .53 |
| ILC | 2 (2.7) | 4 (5.5) | |
| Others | 5 (6.9) | 3 (4.1) | |
| Total | 34 (46.6) | 39 (53.4) | |
*indicates significant p-values (<0.05).
HPV+/EBV+ denotes a co-presence of HPV and EBV. HPV±/EBV± indicates a combination of HPV+/EBV- (HPV presence/EBV absence), HPV-/EBV+ (HPV absence/EBV presence) and HPV-/EBV- (lack of both HPV and EBV).